Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
  • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
  • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/02—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0048—Eye, e.g. artificial tears
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/08—Solutions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
  • A61P27/04—Artificial tears; Irrigation solutions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
  • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
  • A61K47/38—Cellulose; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein

Definitions

• the ocular surface of the eye is a complex biological region that maintains corneal clarity, regulates tear film, and protects the eye from intrusions.
• Ocular surface diseases and disorders negatively affect the surface of the eye, including the cornea and the tear film.
• Ocular surface diseases include Dry Eye Disease (DED), chronic DED, otherwise known as “chronic dry eye syndrome,” “dry eye syndrome,” or “keratoconjunctivitis sicca.”
• DED Symptoms of DED include unclear vision, irritation, itching, dryness, burning, light sensitivity, and possible loss of vision due to ocular surface damage.
• the overall annual burden on the U.S. healthcare system from DED is estimated to be approximately $3.84 billion and the total estimated cost of DED on the population of the U.S. is estimated to be approximately $55.4 billion.
• the prevalence of DED increases linearly with age and appears to be higher in Asian populations.
• formulations include Ambroxol and/or one or more derivatives thereof, dispersed in a carrier.
• the carrier may be water-based (for example, a sterile saline solution) and may include various additives, such as lubricants, preservatives, ionic species, pH-adjusting agents, or other desired additives.
• the disclosed formulations include at least one biocompatible polymer dissolved in the carrier to provide extended release of the ambroxol or chemical derivative.
• biocompatible polymer(s) impregnated with the ambroxol or its chemical derivatives as a vehicle provides extended release of the drug.
• the disclosed formulations are designed for topical application to the eye and may take the form of a solution, gel, drop, ointment, suspension,
• the formulations described herein can be applied to the eye in any suitable manner, such as manually (for example, with eye drops) or with a device that controllably releases the formulation over a predetermined period of time.
• the current clinical approach to treating DED includes topical application of lubricants for mucosa protection, procedures to slow tear drainage (for example, punctal occlusion, whereby punctal plugs are inserted into the tear drainage canal of the eye to prolong tear residence time), therapies to improve meibomian gland function in the lid to retard the evaporation of tears, eye shields (such as in the form of moisture chamber for the eyes), and administering anti-inflammatory agents.
• treatment for DED also can include stimulating water secretion and/or mucus secretion in the eye.
• formulations for topical application to the eye for the treatment of DED and related symptoms are described herein.
• the disclosed formulations and related methods differ from previous treatment approaches.
• the formulations disclosed herein include compounds capable of stimulating the conjunctiva (the mucosal membrane covering the eyeball and the eyelid surface), which studies indicate can contribute to the maintenance of tear film homeostasis on the ocular surface such as in regulating the quantity and quality of tear film.
• the disclosed formulations may improve and, in some cases, cure ocular surface diseases, such as DED.
• the disclosed formulations can be produced in any suitable form, including but not limited to solutions, gels, drops, creams, ointments, suspensions, dispersions, nanoparticulate dispersions, emulsions, microemulsions, liposomes, pastes, or other desired forms.
• the disclosed formulations comprise ambroxol and/or a derivative thereof.
• Ambroxol as referenced herein, has the following chemical formula:
• Ambroxol is a commercially available synthetic mucolytic drug that is sometimes used to stimulate surfactant synthesis in the lung to treat respiratory diseases associated with viscid or excessive mucus.
• Ambroxol is an active ingredient in cough syrup and is also available as a tablet, pastille, dry powder sachet, inhalation solution, drop, ampule, and effervescent tablet.
• ambroxol or any of its chemical derivatives would be useful for treating eye conditions, such as ocular surface disease or DED.
• ambroxol derivatives and “chemical derivatives of ambroxol” refer to compounds derived from ambroxol, precursor compounds for ambroxol, and salt forms of ambroxol, for example, the acid addition salt ambroxol hydrochloride [trans-4-(2-amino-3,5-dibromobenzyl. amino)cyclohexanol hydrochloride].
• a formulation may include at least a first ambroxol derivative and at least a second ambroxol derivative.
• the formulation may also comprise ambroxol.
• the total concentration of ambroxol and chemical derivatives thereof (if present) may be between 0.01 % and 20% by weight based on the total weight of the formulation (w/w). In these and other embodiments, the total concentration of ambroxol and chemical derivatives thereof (if present) may be between 0.01% and 20% by weight based on the total volume of the formulation (w/v), preferably between 0.02 and 10% (w/v). In preferred embodiments, the total concentration of ambroxol and chemical derivatives thereof in the formulation is between 0.5 and 5% (w/v).
• the disclosed formulations also include a carrier in which the ambroxol and/or ambroxol derivative(s) are dispersed. In some embodiments, the carrier may be a buffered saline solution, but also may be an ointment, gel or paste.
• the disclosed formulations may also, in some embodiments, include an extended- release vehicle, such as a biocompatible polymer, dissolved in the carrier or by itself impregnated with ambroxol to hold the ambroxol and slowly release it into the tear film or onto the ocular surface, preferably for an extended release period of up to six months.
• an extended- release vehicle such as a biocompatible polymer
• the biocompatible polymer may be biodegradable or non-biodegradable, depending on desired use and application schedule.
• Example biocompatible polymers that may be used in the disclosed formulations as an extended-release vehicle include but are not limited to poly-2- hydroxyethylmethacrylate (p-HEMA hydrogels), poly(lactic-co-glyco!ic) acid (PLGA), polycaprolactone (PCL), hydroxypropyl cellulose, Anecortave acetate (AnA), gelatin, and/or collagen.
• p-HEMA hydrogels poly-2- hydroxyethylmethacrylate
• PLGA poly(lactic-co-glyco!ic) acid
• PCL polycaprolactone
• hydroxypropyl cellulose hydroxypropyl cellulose
• Anecortave acetate Anecortave acetate
• gelatin and/or collagen.
• collagen Anecortave acetate
• the disclosed formulations may also include one or more additives.
• Additives that may be included in the disclosed formulations include but are not limited to demulcents, preservatives, emollients, ionic species, pH-adjusting agents, and other possible additives.
• formulations include glycerin, carboxymethylcellulose, hydroxyethyl cellulose,
• preservatives examples include benzalkonium chloride and other known preservatives, such as chlorobutanol.
• Emollients may include lanolin preparations, various mineral oils. Omega 3, paraffin, petroleum and waxes. Zinc and or sodium ions may be included in the disclosed formulation as an ionic species, in some embodiments.
• Possible pH-adjusting agents that may be used include citrate buffers (e.g., sodium citrate), borate buffers (e.g., sodium borate), and other acidic or basic compounds. Numerous configurations and variations of additives may be used in the disclosed formulations.
• AQPs aquaporins
• MUC5 AC Mucin 5 AC
• agents that stimulate AQPs in the conjunctiva may also stimulate mucin secretion.
• ambroxol can stimulate the expression of AQP5 in human airway epithelial cells.
• DED conjunctiva
• Ambroxol and chemical derivatives thereof have analgesic as well as anti-inflammatory properties, which may further help relieve eye discomfort, improve tear film homeostasis and/or restore ocular surface health.
• treatment with the disclosed formulations may alleviate DED symptoms, such as unclear vision, irritation, itching, dryness, burning, and/or light sensitivity.
• Frequency of topical application to a subject may vary between patients.
• the disclosed formulations may be applied as frequently as once every ten minutes or as infrequently as once every day.
• the formulation may be applied once, twice, three times or more over a period of one day, two days, three days, four days, five days, or more than five days.
• the formulation may be topically applied with a frequency of at least one time a day to one time a week, or one time a month to one time every six months.
• Frequency of topical application can be determined by numerous considerations, including level of symptom relief provided, pain relief experienced, as well as other pertinent health considerations, such as possible drug interactions.
• the disclosed formulations may be administered using any desired technique.
• the formulations may be eye drops that are administered manually by a user.
• the formulations may be topically applied as a gel or ointment directly to a desired region of the eye using a swab or other type of applicator.
• the disclosed formulations may be delivered using a device designed for immediate formulation release or extended formulation release.
• the formulation may be delivered using one or more of the following devices: external pumps, contact lenses, punctal plugs, muco-adhesive tablets, pills, capsules, pellets, particles, plasters, an ocular insert device, strips placed onto the conjunctiva or cornea, conjunctival inserts or depots, subconjunctival, subtenon, and intravitreal injections, or another suitable types of device.
• devices external pumps, contact lenses, punctal plugs, muco-adhesive tablets, pills, capsules, pellets, particles, plasters, an ocular insert device, strips placed onto the conjunctiva or cornea, conjunctival inserts or depots, subconjunctival, subtenon, and intravitreal injections, or another suitable types of device.
• Efficacy of the formulation in a subject can be assessed by numerous techniques. For example, a patient may self-report symptom relief experienced. In other cases, the eye may be visually assessed or clinical tests, such as the Schirmer's Test, wherein paper strips are inserted into the eye for several minutes to measure tear production, may be used to assess formulation efficacy.
• Schirmer's Test wherein paper strips are inserted into the eye for several minutes to measure tear production

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Ophthalmology & Optometry (AREA)
• Inorganic Chemistry (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Emergency Medicine (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Medicinal Preparation (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (8)

Applications Claiming Priority (4)

Publications (1)

Family

ID=62107036

Family Applications (1)

Country Status (9)

Cited By (1)

Families Citing this family (4)

Citations (5)

Family Cites Families (32)

• 2017
  • 2017-11-10 CN CN201780070126.8A patent/CN109982692A/zh active Pending
  • 2017-11-10 US US15/809,659 patent/US10265280B2/en active Active
  • 2017-11-10 CN CN202210992714.XA patent/CN115607531A/zh active Pending
  • 2017-11-10 CA CA3043327A patent/CA3043327C/en active Active
  • 2017-11-10 JP JP2019546769A patent/JP6871400B2/ja active Active
  • 2017-11-10 ES ES17868628T patent/ES2988280T3/es active Active
  • 2017-11-10 KR KR1020197016988A patent/KR102116303B1/ko active Active
  • 2017-11-10 AU AU2017357755A patent/AU2017357755B2/en active Active
  • 2017-11-10 EP EP17868628.3A patent/EP3538083B1/en active Active
  • 2017-11-10 WO PCT/US2017/061108 patent/WO2018089797A1/en not_active Ceased
• 2019
  • 2019-03-19 US US16/358,517 patent/US20190209496A1/en not_active Abandoned
• 2020
  • 2020-11-02 US US17/087,504 patent/US20210046022A1/en not_active Abandoned
• 2022
  • 2022-07-28 US US17/875,871 patent/US20220378723A1/en not_active Abandoned
• 2024
  • 2024-05-15 US US18/664,847 patent/US20240374540A1/en active Pending

Patent Citations (5)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events